Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management - Takeaways - MDSpire

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

  • By

  • Qi Jian

  • Naueen A. Chaudhry

  • Fanxing Du

  • Ellen Zimmermann

  • Tianze Jiao

  • April 29, 2026

  • 0 min

Share

  • 1

    Inflammatory bowel disease (IBD) affects approximately 3 million people in the US, with treatment focusing on controlling inflammation and maintaining remission.

  • 2

    5-Aminosalicylates (5-ASAs) are first-line therapy for mild to moderate colonic inflammation, while biologics are used for moderate to severe cases.

  • 3

    IBD is linked to a significantly increased risk of cardiovascular disease, including heart failure and myocardial infarction.

  • 4

    The study aims to evaluate the impact of immunomodulators and biologics on major adverse cardiovascular events in older adults with IBD.

  • 5

    Concerns about safety and efficacy contribute to the underutilization of immunomodulators and biologics in older adults with IBD.

Original Source(s)

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

  • by Qi Jian, Naueen A. Chaudhry, Fanxing Du, Ellen Zimmermann, Tianze Jiao

  • April 29, 2026

Related Content

Inflammatory bowel disease (IBD) is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity

Erythrocyte odd-chain fatty acids and the risk of cardiometabolic diseases: a prospective study and updated meta-analysis

Predicting lesion reversal in acute cerebral ischaemia via apparent diffusion coefficient threshold on diffusion-weighted MRI